Cancer Drug Coverage Parity Act of 2011

Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Fee program; policy issues relating to chronic myelogenous leukemia, including H.R. 2746, the "Cancer Drug Coverage Parity Act"; and policy issues relating to Center for Medicare and Medicaid Services' national coverage decisions and rulings.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2746, the Cancer Drug Coverage Parity Act

Client expense: $41,666 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2746 Cancer Coverage Parity Act; Pending Cancer Coverage Parity Act in Senate

Client expense: Not reported · Firm income: $24,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act S.3187, Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act S.3187, Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

Meetings/education regarding incentives for health information technology, Affordable Care Act implementation and other healthcare policy issues. Proposed regulation of medical software. Various issues in the Food and Drug Administration Safety and Innovation Act. H.R. 2746, the Cancer Drug Coverage Parity Act. S. 752 , the Lung Cancer Mortality Reduction Act.

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012

Client expense: $25,001 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program and the Medical Device User Fee program; policy issues relating to chronic myelogenous leukemia, including H.R. 2746, the "Cancer Drug Coverage Parity Act"; and policy issues relating to Center for Medicare and Medicaid Services' coverage decisions and rulings.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746, Cancer Drug Coverage Parity Act

Client expense: $50,500 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746, Cancer Coverage Parity Act

Client expense: $50,500 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2746 Cancer Coverage Parity Act; Pending Cancer Coverage Parity Act in Senate

Client expense: Not reported · Firm income: $24,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Meetings/education regarding incentives for health informatoin technology, Affordable Care Act implementation and other healthcare policy issues. Proposed regulation of medical software. Various issues in the Food and Drug Administration Safety and Innovation Act. H.R. 2746, the Cancer Drug Coverage Parity Act. S. 752, the Lung Cancer Mortality Reduction Act.

Client expense: $380,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act

Client expense: $36,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act

Client expense: $36,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program and the Medical Device User Fee program, and policy issues relating to chronic myelogenous leukemia, including H.R. 2746, the "Cancer Drug Coverage Parity Act."

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $520,389 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act S.3187, Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act S.3187, Food and Drug Administration Safety and Innovation Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2746 Cancer Coverage Parity Act

Client expense: Not reported · Firm income: $24,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: $49,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: $49,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $519,436 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

Cancer Coverage Parity Act, HR.2746; Drug Shortages: HR.3988, S.296, HR.2245; Cardiac & Pulmonary Services, S.2057; H.Res.531 recognizing the 40th Anniversary of the National Cancer Act of 1971; Reauthorization of the Traumatic Brain Injury Act

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Policy issues relating to Patient Protection and Affordable Care Act (Public Law 11-148) implementation; prescription drug and medical device user fee reauthorization; and chronic myelogenous leukemia, including H.R. 2746, the Cancer Drug Coverage Parity Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act Appropriations for health care agencies.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

Client expense: $190,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2746, Cancer Drugs Oral Parity Essential Health Benefits

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.

Client expense: $210,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE